Daily Cosmetic Research Analysis
Today’s top studies span mechanistic dermatology, minimally invasive endocrine therapy, and green nanotechnology. A succinic-acid derivative (335) combined with tranexamic acid suppresses melanogenesis via coordinated proteasomal and autophagic pathways; a prospective cohort clarifies that timing of second-session RFA within 6 months does not change outcomes for large benign thyroid nodules; and myco-synthesized Se- and ZnO-nanoparticles enhance antibiotic activity while downregulating resistanc
Summary
Today’s top studies span mechanistic dermatology, minimally invasive endocrine therapy, and green nanotechnology. A succinic-acid derivative (335) combined with tranexamic acid suppresses melanogenesis via coordinated proteasomal and autophagic pathways; a prospective cohort clarifies that timing of second-session RFA within 6 months does not change outcomes for large benign thyroid nodules; and myco-synthesized Se- and ZnO-nanoparticles enhance antibiotic activity while downregulating resistance genes.
Research Themes
- Proteostasis and autophagy modulation to control skin pigmentation
- Treatment optimization for benign thyroid nodules with image-guided ablation
- Green nanotechnology to combat antimicrobial resistance
Selected Articles
1. Regulation of melanogenesis via ubiquitin-proteasome system and autophagy by 3,3,5-trimethylcyclohexyl succinate dimethylamide and tranexamic acid.
A succinic-acid derivative (335) combined with tranexamic acid suppresses melanogenesis by enhancing tyrosinase ubiquitination (UPS) and autophagic melanosome degradation. TXA improved 335 skin penetration; the 1:10 combination reduced melanin in B16 cells and increased L in a 3D skin model.*
Impact: This study reveals a dual proteostasis mechanism (UPS and autophagy) to reduce pigmentation and demonstrates formulation-relevant skin penetration synergy with TXA, advancing mechanistic and translational foundations for hyperpigmentation therapies.
Clinical Implications: Suggests a potential topical combination strategy to treat hyperpigmentation (e.g., melasma) that could reduce reliance on hydroquinone; clinical studies are needed to establish efficacy, dosing, and safety.
Key Findings
- TXA enhanced skin penetration of 335 and exhibited hydrogen-bonding and hydrophobic interactions with 335.
- A 1:10 335:TXA combination reduced melanin in B16 cells more than either agent alone.
- Transcriptomics implicated modulation of the ubiquitin-proteasome system and autophagy by 335.
- Combination therapy promoted tyrosinase ubiquitination and autophagic melanosome degradation.
- In a 3D skin model, the combination increased skin lightness (L*) and reduced melanin deposition.
Methodological Strengths
- Multi-system validation including HaCaT/B16 cells, MNT-1 melanosome-keratinocyte co-culture, and a 3D skin model
- Mechanistic depth via RNA-seq, molecular docking, and proteostasis pathway assays
Limitations
- Preclinical only; no human clinical trials to confirm efficacy and safety
- Dose-ratio and exposure parameters optimized in vitro may not translate directly in vivo
Future Directions: Formulate and test topical 335+TXA in early-phase clinical trials; characterize long-term safety, pharmacokinetics, and relapse; compare against hydroquinone and retinoid standards.
BACKGROUND: Excessive melanogenesis in skin melanocytes results in hyperpigmentation disorders. OBJECTIVE: This study investigates the combined effects and mechanisms of 3,3,5-trimethylcyclohexanol succinate dimethylamide (335, a succinic acid derivative) and tranexamic acid (TXA) on melanogenesis. METHODS: Skin penetration of 335 was assessed via Raman spectroscopy. Interactions between 335 and TXA were predicted by molecular docking. The anti-melanogenic effect was evaluated by measuring melanin content in human keratinocytes (HaCaT) and mouse melanoma cells (B16). Transcriptome sequencing was performed to identify key pathways by which 335 regulates melanogenesis. Melanosomes were isolated from human melanoma cells (MNT-1) and co-cultured with keratinocytes to validate the specific mechanisms. A 3D melanin skin model was established to evaluate the anti-pigmentation effect of 335 and TXA by analyzing apparent chroma, lightness (L*), and melanin content and distribution. RESULTS: The skin penetration of 335 was enhanced by the addition of TXA, and the two compounds exhibited hydrogen bonding and hydrophobic interactions. The combination of 335 and TXA (1:10) significantly reduced the melanin content in B16 cells compared to individual treatments. Transcriptomics revealed 335 modulates the ubiquitin-proteasome system (UPS) and autophagy. Experimental validation confirmed that 335 and TXA combination inhibited melanin production by promoting ubiquitination degradation of tyrosinase and autophagic degradation of melanosomes. In the 3D skin model, the combination enhanced skin brightness (apparent chroma and L* value) and reduced melanin deposition. CONCLUSION: The combination of 335 and TXA inhibits melanogenesis by UPS-mediated tyrosinase degradation and autophagy-driven melanosome degradation, offering a promising strategy for hyperpigmentation treatment.
2. A prospective comparison of sequential versus interval retreatment with radiofrequency ablation for predominantly solid, large-volume benign thyroid nodules.
In a prospective two-session RFA protocol for large (≥20 mL), predominantly solid benign thyroid nodules, 18-month volume reduction did not differ between sequential (<1 month) and interval (4–6 months) retreatment. Continued shrinkage from 12 to 18 months occurred, and higher energy per unit volume at the second session predicted ≥80% reduction; safety was excellent with same-day discharge.
Impact: Clarifies that timing of second-session RFA within 6 months does not alter efficacy, simplifying scheduling and patient counseling, while identifying a modifiable technical factor (energy/volume) that drives outcomes.
Clinical Implications: For large benign nodules, plan two RFA sessions within 6 months based on logistics and patient preference; prioritize adequate energy/volume at the second session to maximize shrinkage; expect ongoing cosmetic and compressive symptom improvement with low complication risk.
Key Findings
- Overall 12- and 18-month volume reduction rates were 75.7% and 82.7%, respectively.
- No difference in 18-month reduction between sequential (<1 month) vs interval (4–6 months) retreatment (84.1% vs 79.4%; P=0.608).
- Continued shrinkage from 12 to 18 months in both groups (P<.05) with comparable rates (P>.05).
- Higher energy per unit volume at the second session predicted ≥80% reduction (OR 88.3, 95% CI 1.47–532; P=0.038).
- No vocal cord palsy or hematoma; all patients discharged same day.
Methodological Strengths
- Prospective, planned two-session protocol with standardized endpoint of complete echogenic coverage
- Objective assessment of volume reduction and symptom (cosmetic/compressive) changes to 18 months
Limitations
- Small, single-center, non-randomized study with limited generalizability
- No assessment beyond 18 months for regrowth or need for additional sessions
Future Directions: Randomized trials to test energy-dosing strategies and timing, longer-term durability (>24 months), multicenter validation, and cost-effectiveness analyses.
BACKGROUND: Radiofrequency ablation is an effective treatment for benign thyroid nodules. For large nodules ≥20 mL, retreatment within 6 months would lead to a higher volume reduction rate at 12 months than a single treatment. However, the optimal timing of retreatment within the 6-month period has not been determined. This prospective study compared sequential versus interval retreatment with radiofrequency ablation for predominantly solid, large benign thyroid nodules ≥20 mL and identified factors associated with a better volume reduction rate. METHODS: Consecutive patients with predominantly (>80%) solid, cytologically benign large thyroid nodules (≥20 mL) that were undergoing radiofrequency ablation at a tertiary endocrine surgery center were recruited for a planned, 2-session radiofrequency ablation treatment. Group I received sequential retreatment in <1 month, whereas group II received interval retreatment in 4-6 months. For each session, the entire nodule was ablated until it was fully covered with echogenic bubbles. The primary outcome was 18-month volume reduction rate = (baseline volume - 18-month volume)/baseline volume × 100%. Complications, compressive symptoms, and cosmetic symptoms were compared. RESULTS: From 2022 to 2023, 31 nodules (group I: 15, group II: 16) from 30 patients were recruited for a total of 62 ablation sessions. Baseline characteristics including nodule volumes (33.5 [25-40] vs 37.2 [23.9-56.1] mL) and symptoms were comparable (P < .05). The overall 12-month and 18-month volume reduction rates were 75.7% (60.4%-80.9%) and 82.7% (64.7%-87.6%). No significant difference in 18-month volume reduction rate was observed between groups (group I: 84.1% [68.1%-88.3%] vs group II: 79.4% [64.7%-87.6%], P = .608). Both groups had significant further nodule shrinkage from 12 months to 18 months (P < .05), at comparable rates (P > .05), and significant improvement in cosmetic and compressive symptoms (P < .001). A higher energy per unit volume delivered at the second ablation session was the only factor associated with an 18-month volume reduction rate of ≥80% (P = .038, odds ratio: 88.3 [1.47-532]). No vocal cord palsy or hematoma occurred, and all patients were discharged on the same day after each treatment session. CONCLUSION: Continued shrinkage beyond 12 months was observed in large, predominantly solid benign thyroid nodules that received 2-session radiofrequency ablation within 6 months. Varying the time interval to retreatment within 6 months did not affect treatment efficacy. A higher energy per unit volume delivered at the second ablation session was associated with greater volume reduction.
3. Enhanced myco-synthesis of selenium and zinc oxide nanoparticles and evaluating their anticancer activities and role against antibiotic resistance genes in certain bacterial strains.
Fungal myco-synthesis produced Se- and ZnO-nanoparticles that synergized with beta-lactam antibiotics against resistant Gram-negative and Gram-positive strains and reduced resistance gene expression. The nanoparticles also showed selective cytotoxicity against multiple cancer cell lines, and gamma irradiation enhanced production efficiency.
Impact: Demonstrates eco-friendly synthesis of multifunctional nanoparticles that potentiate antibiotics and downregulate resistance genes, offering a promising avenue against antimicrobial resistance with potential translational uses.
Clinical Implications: Raises the possibility of nanoparticle–antibiotic combinations to restore antibiotic efficacy or enable topical antiseptic applications; however, in vivo efficacy, safety, and pharmacokinetics must be established before clinical translation.
Key Findings
- Alternaria alternata enabled green synthesis of Se-NPs and ZnO-NPs with successful physicochemical characterization.
- Se-NPs and ZnO-NPs showed antibacterial activity and synergized with penicillin, ceftriaxone, and cefepime against resistant strains.
- Exposure to NP–antibiotic combinations reduced expression of antibiotic resistance genes.
- Nanoparticles exhibited potent cytotoxicity against MCF-7, A549, and HepG2 cancer cells with lower toxicity to HFB-4 cells.
- Gamma irradiation enhanced production efficiency of both nanoparticles.
Methodological Strengths
- Integrated assessment of antimicrobial synergy and resistance gene expression with multiple antibiotics and strains
- Use of diverse cancer and normal cell lines to profile cytotoxic selectivity
Limitations
- Findings are limited to in vitro systems without in vivo validation of efficacy and toxicity
- Mechanistic basis for resistance gene downregulation and detailed dose–response/MIC data are not fully elucidated
Future Directions: Evaluate in vivo antimicrobial efficacy, biodistribution, and safety; dissect molecular mechanisms of resistance gene modulation; test performance in biofilm models and topical formulations.
BACKGROUND: In an array to check microbial resistance against generally used antibiotics, it is essential to create innovative and efficient antimicrobial agents. Therefore, nanoparticles (NPs) with their antimicrobial activities describe an effective solution. In this study, we synthesized Selenium nanoparticles (Se-NPs) and zinc oxide nanoparticles (ZnO-NPs) using Alternaria alternata fungus, then their characterization were evaluated using several techniques. RESULTS: We explored the potential of antimicrobial impact of Se-NPs and ZnO-NPs against negative and positive grams antibiotic resistance bacterial strains in combination with penicillin, Ceftriaxone and Cefipime. Moreover, antibiotic resistance gene expression was assessed after those treatments. The results demonstrated that Se-NPs and ZnO-NPs displayed antibacterial properties, while the expression of antibiotic resistance genes decreased when exposed to a combination of NPs and antibiotics. This suggests the presence of both synergistic and additive effects in these treatments. Furthermore, the cytotoxic effects of Se-NPs and ZnO-NPs were assessed, revealing their potent anticancer properties against MCF-7, A549, and HepG2 cancer cells and lower cytotoxic values for HFB-4 standard cell line. Ultimately, the production efficiency of both NPs was enhanced through gamma irradiation. CONCLUSIONS: According to the results, it seems that the green synthesis of Se-NPs and ZnO-NPs promotes environmental sustainability and cost-effective approach. This study provides insights into the development of new antibacterial and anticancer agents . The eco-friendly production of nanoparticles suggests also a sustainable approach to combating bacteria resistant to antibiotics.